Leadership

Patricia S. Andrews serves as the Chief Executive Officer and Global Head of Oncology. Prior to joining Sumitomo Dainippon Pharma Oncology (SDP Oncology), Ms. Andrews spent 7 years at Boston Biomedical, Inc., one of the predecessor companies, and served as Chief Executive Officer and Chief Operating Officer.

Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a U.S.-based biopharmaceutical company. In this role, she led the transition from a clinical-stage research and development organization to a successful commercial enterprise with the launch of its first-for-the-company, first-in-class, first-in-disease, orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.

Prior to her experience at Incyte, Ms. Andrews spent 17 years at Pfizer Inc., culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, at the time a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews is an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. and serves on the board of GlycoMimetics [Nasdaq: GLYC]. Ms. Andrews received her M.B.A. from the University of Michigan and a B.A. from Brown University.

Edgar Braendle, M.D., Ph.D. serves as the Chief Medical Officer and Global Head of Development. Prior to joining SDP Oncology, Dr. Braendle spent 3 years at Boston Biomedical, Inc., one of the predecessor companies, and served as Executive Vice President, Head of R&D and Chief Medical Officer.

Dr. Braendle has more than 20 years of industry experience leading clinical development and oncology diagnostics and treatments. Prior to joining Boston Biomedical, he served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Previously, he spent more than a decade at Novartis Pharmaceuticals, culminating in his role as Senior Vice President and Global Head of Companion Diagnostics. In this role, Dr. Braendle led the company’s precision medicine approach, delivering all complementary and companion diagnostics for Novartis Medicines, and driving exploratory biomarker development. In an earlier position as Vice President, Global Head of Oncology Biologics, he developed Novartis oncology biologics in early to late stages, successfully filing 8 investigational new drug applications.

Dr. Braendle received a medical degree and training in hematologic malignancies and solid tumor oncology, pharmacology and urology at the University of Aachen, University of Bonn, and the University of Ulm in Germany.

Michelle A. Flores serves as Vice President, Head of Legal Affairs. In her role, she leads and manages the legal department at Sumitomo Dainippon Pharma Oncology (SDP Oncology), where she provides strategic leadership on a broad range of legal matters, including corporate and commercial transactions, regulatory matters, compliance, intellectual property, litigation management, employment, privacy and records management.

Ms. Flores has 20 years of legal experience and was named one of the 2020 Top Women in Law by Massachusetts Lawyer Weekly. Prior to joining SDP Oncology, Ms. Flores served 5 years as Associate General Counsel at Sunovion Pharmaceuticals, Inc., a wholly owned subsidiary of SDP Oncology’s parent company, Sumitomo Dainippon Pharma Co., Ltd. At Sunovion, she was a two-time winner of the company’s prestigious President’s Circle of Excellence Award and was most recently responsible for litigation, business development/contracts and records and information. As a trained chemist, Ms. Flores started her legal career as an attorney within ExxonMobil Corporation’s legal department. After departing ExxonMobil, Ms. Flores held extended tenures at Nixon Peabody LLP and Foley & Lardner LLP, where she focused on intellectual property litigation, patent prosecution and corporate law.

Ms. Flores earned her law degree from the University of Colorado and her M.S. in environmental science from the University of Texas. She received a B.S. in chemistry from Tufts University.

Masashi Murata, Ph.D. serves as Chief Strategy Officer, Global Strategy and Planning, as well as the Interim Steward of US Global Research. In this role, he formulates and monitors the execution of corporate strategy and associated plans in support of the company’s vision, mission, and business imperatives. Prior to joining SDP Oncology, Dr. Murata served as Chief Strategic Officer, Global Strategy and Planning and Vice President of Corporate Strategy and Planning at Boston Biomedical, Inc., one of the predecessor companies.

Dr. Murata has more than 26 years of experience in the biopharmaceutical industry, leading multiple clinical development programs in Japan and managing collaborations and alliances. Dr. Murata also oversaw clinical development programs, drug discovery, and preclinical research programs at Sumitomo Dainippon Pharma Co., Ltd., culminating in the role of Director in the Global Strategy Group of the Global Oncology Office. Dr. Murata also led several preclinical-stage research programs, including in-house at Sumitomo Dainippon Pharma and third-party collaboration programs at AstraZeneca plc in immunology, gene therapy, and oncology.

Dr. Murata earned his Doctor of Philosophy and Faculty of Sciences degrees from Kyoto University in Kyoto, Japan, and has also co-authored articles in several peer-reviewed publications.

Joseph Pane serves as Senior Vice President, Chief Human Resources Officer. In this role and throughout his career, Mr. Pane strives to create the best environment for the business to succeed and employees to thrive. Prior to joining Sumitomo Dainippon Pharma Oncology (SDP Oncology), Mr. Pane spent 4 years at Boston Biomedical, Inc., one of the predecessor companies, and served as Vice President of Human Resources & Administration. At Boston Biomedical, he stewarded the people and organizational activities to support the merger of Boston Biomedical and Tolero Pharmaceuticals and the subsequent globalization of research and development.

Mr. Pane has more than 30 years of experience leading human resource teams at well-known global companies and biotech start-ups. Prior to his tenure at Boston Biomedical, Mr. Pane spent 6 years at Sunovion Pharmaceuticals, Inc., where he was Executive Director & Head, Human Resources Business Partner Group. In this leadership role, Mr. Pane and his team supported Sunovion’s multiple product launches including the blockbuster drug Latuda, two acquisitions, European operations and global clinical development. Earlier in his career, Mr. Pane was Vice President, Human Resources at Oscient Pharmaceuticals Corporation, a public commercial-stage pharmaceutical company, in which he developed and managed human capital strategy for the Genome Therapeutics merger with GeneSoft Pharmaceuticals. Formerly, Mr. Pane also held human resources leadership roles at Genome Therapeutics, Inc. and Medtronic, Inc.

Mr. Pane received a Master of Education from Salem State University in Massachusetts. He also received a Certificate of Advanced Graduate Study (CAGS) in Human Resources from Southern New Hampshire University and a B.S. in History and Spanish from the University of Massachusetts Lowell.